Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis
Acute myeloid leukaemia (AML) is a hard to treat blood cancer. Mutations in FLT3 are common among the genetic aberrations that characterise the cancer. Patients initially react to FLT3 inhibitors but drug resistance is a hinder to successful therapy. To better understand the mechanisms leading to dr...
Saved in:
| Main Authors: | Jingmei Yang, Ran Friedman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Biochemistry and Biophysics Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405580824002589 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context
by: Suvir Singh, et al.
Published: (2024-04-01) -
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice
by: Monica Messina, et al.
Published: (2024-12-01) -
Sweet syndrome induced by FLT3 inhibitors: case report and literature review
by: Linhui Yang, et al.
Published: (2024-12-01) -
Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia
by: Qi Zhou, et al.
Published: (2025-02-01) -
FLT3: A narrative review
by: Nikhil M Kumar, et al.
Published: (2025-01-01)